Skip to content
CheckOrphan
  • Home
  • About Us
  • Log In
  • News
    • All News
    • Finance
    • Treatment
    • People
    • Research
  • Videos
  • Treatments
  • Clinical Trials
  • Access Programs
    • About Access Programs
  • Diseases
  • Events
  • Networks
  • Research
Main Menu
  • News
    • All News
    • Finance
    • Treatment
    • People
    • Research
  • Videos
  • Treatments
  • Clinical Trials
  • Access Programs
    • About Access Programs
  • Diseases
  • Events
  • Networks
  • Research
  • Home
  • About Us
  • Log In

Subscribe for Free Newsletter

Email *

Type *

* Required Field
Email Marketing Services by Benchmark

Generate RSS

  1. Home
  2. /
  3. Video
  4. /
  5. klippel Trenaunay Syndrome

klippel Trenaunay Syndrome

April 17, 2015abidemi.uruejoma@gmx.ch
https://www.youtube.com/watch?v=Erd86USCi2s

klippel Trenaunay Syndrome

News

  • NeuroSense Unveils Promising Phase 2b Data for PrimeC in ALS, Highligh
  • Uplizna® (Inebilizumab-cdon) is Now the First and Only FDA-Approved T
  • ResVita Bio Announces that RVB-003 was Granted FDA Orphan Drug Designa
  • Minovia Therapeutics Receives FDA Clearance of Second IND Application,
  • U.S. FDA Grants Paige Breakthrough Device Designation for AI Applicati
More News

Access Programs

  • Jonsson Comprehensive Cancer Center – Progressive Metastatic Cas
  • Massachusetts General Hospital – Healthy Naturally Cycling Women
  • Kite, A Gilead Company – Relapsed/Refractory Primary Mediastinal
  • Kite, A Gilead Company – Relapsed/Refractory High-Grade B-Cell L
  • Kite, A Gilead Company – Relapsed/Refractory Transformed Follicu
More Access Programs
pw

About CheckOrphan

CheckOrphan is a non-profit organization located in Basel, Switzerland and Santa Cruz, California that is dedicated to rare, orphan and neglected diseases. CheckOrphan offers users an interactive and dynamic platform for all these diseases. This strategy allows visitors to be updated daily on all the latest news and interact with people internationally. This is essential, because due to the nature of these diseases, there is not a large concentration of individuals within any given proximity.
Click here to know more About Us

Your email is important to us

Each email is sent to a CheckOrphan staff member and will be answered. We only use a contact form to avoid spam.

    Copyright © 2025 CheckOrphan.
    Developed by: Gonza.io logo Developed by: WebOptimalSolutions Powered by: Cloudscale logo